Page 144 - CW E-Magazine (24-12-2024)

Top Stories Pharmaceuticals

THE WAY FORWARD QUALITY CONTROL

India’s transition to circular economy requires Aurobindo, Glenmark, Zydus recall products in US

collective action; R&D, industry collaboration important: over manufacturing issues

Amitabh Kant Drug makers Aurobindo Pharma, are used to treat high blood pressure.
“India’s transition to a circular India, CEEW, and RMI explores the Glenmark and Zydus are recalling The company initiated the Class II
economy is not the responsibility of any immense potential of circularity spans products in the US market due to manu- nationwide (US) recall on November 1
single stakeholder. It requires collective across sectors, from transforming agri- facturing issues, according to the US this year.
action, deliberate and coordinated cultural waste into value-added products health regulator.
effort across industries, and must be driven to optimising resource use in construc- The USFDA further stated that
by R&D,” said Mr. Amitabh Kant, tion amidst accelerating urbanisation”. As per the latest Enforcement Zydus Pharmaceuticals (USA) Inc. is
G20 Sherpa for India, at the launch Report of US Food and Drug Administra- recalling 4,404 packs of Esomeprazole
of a collaborative discussion paper, Ms. Ghate added, “This is not tion (USFDA), Aurobindo Pharma USA Magnesium for Delayed-Release Oral
‘Unlocking India’s Circular Economy merely a call to recycle but a call to Inc., a subsidiary of Hyderabad-based Similarly, a US-based subsidiary Suspension (40-mg) due to a labelling
Potential: Insights Across Seven Key reimagine systems, foster resilience, drug maker, is recalling over 1-lakh of Glenmark Pharmaceuticals is re- error. The medication is used to treat
Sectors’, in New Delhi recently. The paper and create new value across industries. bottles of Cinacalcet tablets in multiple calling around 90,000 bottles of Dilti- certain stomach and oesophagus pro-
was launched at a session hosted by the RMI, along with CEEW and WRI India, strengths. The New Jersey-based fi rm is azem Hydrochloride extended-release blems. The company initiated the
World Resources Institute (WRI) India, To achieve this, we must work collectively – through this discussion paper has made recalling the product due to “GMP De- capsules (multiple strengths) in the US nationwide recall of the affected packs
Rocky Mountain Institute (RMI), and government, industry, think tanks, and an attempt to highlight the power of viations: Presence of N-nitroso Cina- market. Glenmark Pharmaceuticals on November 14.
the Council on Energy, Environment civil society – to build an ecosystem collective action.” calcet impurity above FDA recom- Inc., USA is recalling the affected lot
and Water (CEEW). The paper pro- that embeds circularity at scale.” mended interim limit,” the US health of Diltiazem Hydrochloride extended- As per the USFDA, a Class II recall
vides actionable recommendations to Dr. Ghosh, said, “The circular eco- regulator said. release capsules due to “cGMP Devi- is initiated in a situation in which the
advance circularity in sectors includ- Leading voices from the govern- nomy is not just about recycling; it’s ations: Presence of N-nitroso-Desme- use of, or exposure to, a violative pro-
ing solar, batteries, steel, construction, ment, academia, and industry, such as about rethinking how we design, use, The company initiated the Class II thyl-Diltiazem impurity above FDA duct may cause temporary or medically
agriculture, wastewater, and municipal Mr. Sree Kumar Kumaraswamy (Pro- and repurpose resources. It’s crucial for recall on November 7 this year. Cina- recommended interim limit”, the US reversible adverse health consequences
solid waste. gram Director – Clean Air Action, WRI our sustainable development, energy calcet tablets are used to treat hyper- health regulator stated. Diltiazem Hydro- or where the probability of serious
India), Ms. Akshima Ghate (Managing security, and climate action goals. As parathyroidism. chloride extended-release capsules adverse health consequences is remote.
In his keynote speech, Mr. Kant Director, RMI), and Dr. Arunabha Indians, we know waste can be wealth.
said, “Circular economy offers a really Ghosh (CEO, CEEW) also came It’s time to unlock its business oppor- Lupin acquires 3 anti-diabetes trademarks
compelling solution to the dilemma that together for a panel discussion at the tunity – from steel to silicon to sludge.”
India is facing of urbanisation and session to deliberate on the practical from Boehringer Ingelheim
industrialisation. India’s vibrant startup steps needed to embed circularity into The paper calls for investment in
ecosystem and digital advancements India’s economic fabric. advanced recycling technologies to im- Lupin has acquired anti-diabetes
position us uniquely to revolutionise prove material recovery rates and reduce trademarks Gibtulio, Gibtulio Met and
resource management and accelerate Mr. Madhav Pai, CEO, WRI India, reliance on virgin resources. The deve- Ajaduo from Boehringer Ingelheim
the transition to a circular economy. said, “The discussion paper by WRI lopment of cohesive policy and regula- International, strengthening its diabetes
tory frameworks, such as Extended footprint in the country.
Producer Responsibility and Circular
Product Design Standards, is also vital to The trademark rights for these
incentivising waste reduction and reuse. brands will be transferred to Lupin by
Further, building robust infrastructure March next year, Lupin said, without
for waste collection and recycling, es- giving fi nancial details.
pecially in underserved regions, will Gibtulio (empaglifl ozin), Gibtulio with diet and exercise, the company
ensure that materials are effi ciently Lupin has been marketing Gib- Met (empaglifl ozin + metformin), and said. Empaglifl ozin is also indicated to
recovered and reused. These measures, tulio and Gibtulio Met since 2016 Ajaduo (empaglifl ozin + linagliptin) reduce the risk of cardiovascular death
coupled with collaboration across govern- and Ajaduo since 2018 in the Indian belong to a novel class of oral anti- in adults with type-2 diabetes, and the
ment, industry, and civil society, could market through existing co-marketing diabetic drugs, that are indicated to risk of cardiovascular death and hospi-
unlock signifi cant economic value while agreements with Boehringer Ingelheim improve glycaemic control in adults talisation for heart failure in adults with
mitigating environmental harm. India. with type-2 diabetes mellitus, along chronic kidney disease, the note said.

144 Chemical Weekly December 24, 2024 Chemical Weekly December 24, 2024 145

Contents Index to Advertisers Index to Products Advertised